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ABSTRACT
Background: Breast cancer survival is higher in less deprived women, even 
amongst women whose tumor was screen-detected, but reasons behind this have 
not been comprehensively investigated.
Methods: The excess hazard of breast cancer death in 20,265 women diagnosed 
with breast cancer, followed up to 2012, was estimated for screen-detected and non-
screen-detected women, comparing more deprived to less deprived women using 
flexible parametric models. Models were adjusted for individual and tumor factors, 
treatment received and comorbidity. For screen-detected women, estimates were 
also corrected for lead-time and overdiagnosis.
Results: The excess hazard ratio (EHR) of breast cancer death in the most 
deprived group, adjusted only for age and year of diagnosis, was twice that of 
the least deprived among screen-detected women (EHR=2.12, 95%CI 1.48-2.76) 
and 64% higher among non-screen-detected women (EHR=1.64, 95%CI 1.41-
1.87). Adjustment for stage at diagnosis lowered these estimates by 25%. Further 
adjustment had little extra impact. In the final models, the excess hazard for the 
most deprived women was 54% higher (EHR=1.54, 95%CI 1.10-1.98) among screen-
detected women and 39% higher (EHR=1.39, 95%CI 1.20-1.59) among non-screen-
detected women.
Conclusion: A persistent socio-economic gradient in breast cancer-related death 
exists in this cohort, even for screen-detected women. The impact of differential 
lifestyles, management and treatment warrant further investigation.
INTRODUCTION
In the UK, deprived women have lower breast 
cancer survival [1–5]. This has also been found to be 
the case in other countries [6–9]. The overall difference 
in breast cancer survival between affluent and deprived 
women was not modified in the UK by introduction of 
screening in 1989 [10] and remains despite a mature 
screening program and a recent narrowing of the survival 
gap [11]. The discrepancy in survival by deprivation 
remains a key focus of public health policy [12].
We have previously examined this cohort 20, 265 
women diagnosed in the West Midlands region of England 
from 1989 to 2011 [5]. We reported higher breast cancer 
survival in less deprived women amongst both women 
whose cancer was detected following symptoms, as well 
as amongst women whose tumor was screen-detected, 
and thus likely to be asymptomatic. In the same analysis, 
we showed no differences in breast cancer survival 
between ethnic groups. Together, these findings suggest 
that, although screening confers a survival benefit to all 
women, there are still wide, unexplained disparities in 
breast cancer survival by deprivation.
Whereas socio-economic inequalities overall may 
partly be explained by later presentation, leading to 
more advanced disease [13–15] it is less probable that 
stage of disease explains socio-economic differences 
amongst screen-detected women who are asymptomatic 
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at presentation. Reasons for this residual socio-economic 
gradient in breast cancer survival in screen-detected 
women have not yet been comprehensively investigated. 
Screen-detected women provide an ideal opportunity to 
examine these since the differences in stage at presentation 
between more and less deprived women is substantially 
reduced.
Here we model the excess hazard of breast cancer 
death (i.e. the hazard of death on top of the expected 
hazard of death, therefore related to breast cancer) amongst 
more deprived compared to more affluent women, in order 
to examine whether variations in tumor characteristics, 
pre-existing comorbidities or surgery might explain 
deprivation-specific inequalities in breast cancer survival 
where women have been diagnosed asymptomatically.
RESULTS
Cohort characteristics
We included in the analysis 20,265 women who had 
a first primary malignant breast tumor (mean age 57.5 
years, standard deviation=5.0, 96.4% of those eligible) and 
who were continuously eligible for screening from the age 
of 50 onwards. We compared women whose breast cancer 
was screen-detected (n=10,502, 51.8%) to women who 
were not screen-detected (n=9,763, 48.2%).
Most women were diagnosed with localized disease 
(60.0%) and were alive at the end of follow-up (81.6%, 
Table 1). There were more women in the less deprived 
categories (e.g. 22.1% in the least deprived compared with 
17.0% in the most deprived). Women in the more deprived 
categories were less likely to have local disease (58.0% in 
the most deprived compared to 62.2% in the least deprived 
women, χ2 p-value<0.001) or first surgery within 2 weeks 
of diagnosis (31.3% compared to 37.2%, p<0.001) and 
more likely to have larger tumors (6.2% compared to 
4.7%, p<0.001), comorbidities (7.3% compared to 4.0%, 
p<0.001) and be deceased by the end of follow-up (21.8% 
compared to 16.2%, p<0.001). They were also slightly 
older (e.g. 11.6% compared to 9.3% in the oldest age 
group, p=0.04). Grade did not vary across deprivation 
categories (p=0.260), nor did screening history (p=0.120).
Excess hazard of breast cancer death
Among non-screen-detected women, the excess 
hazard of death from breast cancer, adjusted only for age 
and year of diagnosis, within five years of diagnosis was 
64% higher in the most deprived group compared with 
the least deprived group (EHR=1.64, 95%CI 1.41-1.87) 
(Table 2) and more than double among screen-detected 
women (EHR=2.12, 95%CI 1.48-2.76). These hazard 
ratios reduced by around 25% after adjustment for stage of 
disease. Tumor characteristics and treatment did not have 
any notable impact. The inclusion of comorbidity reduced 
the excess hazard ratios slightly in both groups.
There was a time-varying effect of age in the non-
screen-detected group. Time to surgery did not improve 
the fit of the final model for the screen-detected group 
but was included for non-screen-detected women. No 
interactions were found. In the final models, the excess 
hazard for women in the most deprived group was 39% 
higher (EHR=1.39, 95%CI 1.20-1.59) among non-screen-
detected women, and 54% higher (EHR=1.54, 95%CI 
1.10-1.98) for the screen-detected.
Sensitivity analysis
The sensitivity analysis suggested that use of the 
complete case data underestimated the excess hazard 
which was adjusted only for age and year of diagnosis, 
(by 5% in non-screen-detected and 8% in screen-detected). 
The analysis also showed that results for the final model 
were likely to be robust; when all the less deprived 
women had favorable tumors and all the more deprived 
had unfavorable, excess mortality remained higher for 
deprived women, by 19% in non-screen-detected and 49% 
in screen-detected women (Table 3).
DISCUSSION
We have demonstrated a socio-economic gradient 
in breast cancer-related death in the West Midlands 
among women eligible for screening regardless of 
whether the woman’s breast cancer was screen-detected 
or not. This difference persists after adjustment for 
stage of disease at diagnosis (including size of tumor), 
histology, surgery (including time to surgery) and pre-
existing comorbidities.
The data used for this study come from a center of 
excellence, individually linked for each woman to various 
data sources with good completeness on most variables. 
Uniquely and importantly, our cohort for analysis included 
only women aged 50 to 70 years old who had been 
continuously eligible for screening, in order to exclude 
women diagnosed within the screening age range but who 
had no opportunity for the cancer to be screen-detected at 
the time of diagnosis.
We used robust, up-to-date statistical techniques 
to estimate the differences in the excess hazard of 
cancer death between more affluent and more deprived 
women. We used deprivation- and ethnicity-adjusted 
life tables in order to obtain the most accurate correction 
for background mortality [16, 17]. We also corrected 
for lead time bias [18, 19] and overdiagnosis, which 
allowed a direct comparison between screen-detected and 
non-screen-detected women [20, 21]. Studies in other 
countries have looked at the impact of screening and 
socio-economic status on breast cancer survival, and come 
to similar conclusions to this study [7, 8, 22]. However, 
none have used the net survival framework (either net 
survival or the excess hazard of breast cancer death), nor 
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adjusted for lead-time or overdiagnosis as we do here. As 
such, they may have overestimated the difference between 
deprivation groups. In addition, none of these previous 
studies has taken place in England and thus they have 
not examined the particular context of the NHS Breast 
Screening Programme.
Table 1: Cohort and tumor characteristics by deprivation category, n (%) and mean [standard deviation] for 
continuous variables
N=20,265 Least deprived
1
2 3 4 Most deprived
5
Total p-value 
(χ2)
Age at diagnosisa
 Mean [sd] 57.2 [4.9] 57.6 [5.1] 57.5 [5.0] 57.5 [5.1] 57.7 [5.1] 57.5 [5.0]
0.040
 50-54 1,576 (35.2) 1,556 (33.7) 1,407 (33.7) 1,218 (34.3) 1,122 (32.5) 6,879 (33.9)
 55-59 1,442 (32.2) 1,412 (30.6) 1,307 (31.3) 1,084 (30.6) 1,089 (31.6) 6,334 (31.3)
 60-64 1,042 (23.3) 1,141 (24.7) 990 (23.7) 847 (23.9) 840 (24.3) 4,860 (24.0)
 65-70 418 (9.3) 505 (10.9) 472 (11.3) 397 (11.2) 400 (11.6) 2,192 (10.8)
Vital status at end of follow up
 Alive 3752 (83.8) 3854 (83.5) 3421 (81.9) 2810 (79.2) 2699 (78.2) 16,536 (81.6)
<0.001
 Dead 726 (16.2) 760 (16.5) 755 (18.1) 736 (20.8) 752 (21.8) 3,729 (18.4)
Screening historyb
 SD 2,320 (51.8) 2,380 (51.6) 2,232 (53.4) 1,830 (51.6) 1,740 (50.4) 10,502 (51.8)
0.120
 Not SD 2,158 (48.2) 2,234 (48.4) 1,944 (46.6) 1,716 (48.4) 1,711 (49.6) 9,763 (48.2)
Period of diagnosisa
 1989-1994 200 (4.5) 167 (3.6) 161 (3.9) 136 (3.8) 137 (4.0) 801 (4.0)
<0.001
 1995-2000 934 (20.9) 866 (18.8) 787 (18.8) 651 (18.4) 600 (17.4) 3,838 (18.9)
 2001-2006 1,765 (39.4) 1,781 (38.6) 1,555 (37.2) 1,383 (39.0) 1,300 (37.7) 7,784 (38.4)
 2007-2011 1,579 (35.3) 1,800 (39.0) 1,673 (40.1) 1,376 (38.8) 1,414 (41.0) 7,842 (38.7)
Extent of disease
 Local 2,786 (62.2) 2,795 (60.6) 2,539 (60.8) 2,048 (57.8) 2,002 (58.0) 12,170 (60.1)
<0.001
 Regional 1,305 (29.1) 1,435 (31.1) 1,303 (31.2) 1,169 (33.0) 1,146 (33.2) 6,358 (31.4)
 Distant 98 (2.2) 97 (2.1) 78 (1.9) 106 (3.0) 104 (3.0) 483 (2.4)
 Missing 289 (6.5) 287 (6.2) 256 (6.1) 223 (6.3) 199 (5.8) 1,254 (6.2)
Histological group
 Ductal 3,274 (73.1) 3,297 (71.5) 2,962 (70.9) 2,475 (69.8) 2,497 (72.4) 14,505 (71.6)
0.001
 Lobular 673 (15.0) 784 (17.0) 690 (16.5) 581 (16.4) 486 (14.1) 3,214 (15.9)
 All other 509 (11.4) 512 (11.1) 503 (12.0) 463 (13.1) 442 (12.8) 2,429 (12.0)
 Missing 22 (0.5) 21 (0.5) 21 (0.5) 27 (0.8) 26 (0.8) 117 (0.6)
Grade of tumor
 I 932 (20.8) 932 (20.2) 858 (20.5) 692 (19.5) 671 (19.4) 4,085 (20.2)
0.260
 II 1,897 (42.4) 2,027 (43.9) 1,778 (42.6) 1,537 (43.3) 1,436 (41.6) 8,675 (42.8)
 III 1,292 (28.9) 1,286 (27.9) 1,222 (29.3) 1,019 (28.7) 1,072 (31.1) 5,891 (29.1)
 Missing 357 (8.0) 369 (8.0) 318 (7.6) 298 (8.4) 272 (7.9) 1,614 (8.0)
(Continued )
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Information on individual deprivation status is 
unobtainable from any of the data sources available. We 
thus defined deprivation ecologically using the validated 
score temporally closest to the women’s date of diagnosis, 
in order to measure as closely as possible the impact 
of deprivation on diagnosis and cancer management. 
These ecological data provide only a proxy measure of 
the underlying variable of interest. They are susceptible 
to the ecological fallacy, as well as to temporal change. 
In reality it is probable that these ecologically-based 
analyses underestimate the true underlying differences 
between women of different socio-economic status. This 
could be examined in a dataset where both ecological and 
individual measures of deprivation could be derived.
We examined the potential impact of missing data 
upon our results via a sensitivity analysis. This suggests 
that the differences we observe in the excess hazard 
of breast cancer death are robust to the (unknown) 
distributions of missing data. In reality, we consider it 
probable that the true (unmeasurable) excess hazard ratio 
falls between the complete-case and sensitivity estimate.
We determined cancer stage using both extent 
of disease and tumor size at diagnosis. Together these 
variables resulted in a sizeable reduction in excess 
mortality estimates for both screened and non-screen-
detected women. Although extent of disease was strongly 
associated with deprivation in both screening groups in 
this study, the proportion of regional and advanced tumors 
was particularly high in the most deprived category of 
screen-detected women. These women also had tumors 
that were larger. This raises the possibility that the more 
deprived women with symptoms may use screening as an 
entry point more frequently than the less deprived women 
with symptoms; that is, attend ‘routine’ screening when 
N=20,265 Least deprived
1
2 3 4 Most deprived
5
Total p-value 
(χ2)
Size of tumor (mm) a, c
 Mean [sd] 20.1 [15.4] 20.5 [15.7] 21.1 [17.5] 21.4 [17.1] 22.4 [17.4] 21.0 [16.6]
<0.001
 0 - 20 2,490 (55.6) 2,486 (53.9) 2,242 (53.7) 1,839 (51.9) 1,707 (49.5) 10,764 (53.1)
 20 - 50 1,380 (30.8) 1,484 (32.2) 1,387 (33.2) 1,183 (33.4) 1,251 (36.3) 6,685 (33.0)
 50 mm+ 211 (4.7) 237 (5.1) 226 (5.4) 199 (5.6) 215 (6.2) 1,088 (5.4)
 Missing 397 (8.9) 407 (8.8) 321 (7.7) 325 (9.2) 278 (8.1) 1,728 (8.5)
Charlson score
 0 4,301 (96.0) 4,444 (96.3) 3,991 (95.6) 3,345 (94.3) 3,199 (92.7) 19,280 (95.1)
<0.001
 1 77 (1.7) 90 (2.0) 99 (2.4) 100 (2.8) 151 (4.4) 517 (2.6)
 2 92 (2.1) 71 (1.5) 68 (1.6) 84 (2.4) 77 (2.2) 392 (1.9)
 3 8 (0.2) 9 (0.2) 18 (0.4) 17 (0.5) 24 (0.7) 76 (0.4)
Surgery
 No 288 (6.4) 306 (6.6) 252 (6.0) 289 (8.2) 279 (8.1) 1,414 (7.0)
<0.001
 Yes 4,190 (93.6) 4,308 (93.4) 3,924 (94.0) 3,257 (91.8) 3,172 (91.9) 18,851 (93.0)
Total 4,478 (100) 4,614 (100) 4,176 (100) 3,546 (100) 3,451 (100) 20,265 (100)
Time from diagnosis to first surgerya (among those who had surgery, n=18,851)
 Mean [sd] 
(days)
21.6 [23.6] 22.6 [24.9] 22.1 [23.4] 23.5 [25.5] 23.5 [25.2] 22.6 [24.5]
<0.001
 0 – 2 weeks 1,557 (37.2) 1,530 (35.5) 1,313 (33.5) 1,036 (31.8) 992 (31.3) 6,428 (34.1)
 2 - 6 weeks 2,317 (55.3) 2,408 (55.9) 2,336 (59.5) 1,934 (59.4) 1,914 (60.3) 10,909 (57.9)
 6 + weeks 289 (6.9) 341 (7.9) 250 (6.4) 270 (8.3) 248 (7.8) 1,398 (7.4)
 Missing 27 (0.6) 29 (0.7) 25 (0.6) 17 (0.5) 18 (0.6) 116 (0.6)
Total 4,190 (100) 4,308 (100) 3,924 (100) 3,257 (100) 3,172 (100) 18,851 (100)
a Fitted as a continuous variable in the model
b SD=screen detected, not SD=not screen-detected
c Grouped here according to TNM criteria: T1 >=20 mm, T2 20mm-50 mm, T3 >=50 mm [45].
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they suspect cancer or are experiencing breast symptoms, 
in place of visiting their GP. Qualitative studies could 
explore this hypothesis further by examining women’s 
motivations for attending screening by deprivation. 
Detailed examination of screening attendance patterns 
amongst all women could also be conducted, for example, 
examining the proportion of appointments attended on 
time, late, or not at all amongst more affluent compared to 
more deprived groups. Additionally, symptom awareness 
may be lower among the more deprived women [23, 24], 
leading to more women with regional or distant disease 
being diagnosed via the screening service. Either way, our 
data suggest that stage of disease, and thus timeliness of 
presentation, play a role in deprivation-specific differences 
Table 2: Screening-specific excess hazard ratios at five years after diagnosis for each model in turn, comparing the 
most deprived to the least deprived group (reference)
Model Variable Form of variable in the 
model
Excess Hazard Ratios  
(95% CIs)
Non-screen-
detected
Screen-
detected
Non-screen-detected
(n=8,962)
Screen-detected
(n=8,541.5)a
1 = Baseline (3 df 
for baseline 
hazard)
Age (continuous) Non-linear (2 df); 
time- varying 
effect (1df)
Linear 1.64 (1.41-1.87) 2.12 (1.48-2.76)
Year of diagnosis 
(continuous)
Linear Linear
Deprivation (categorical) Linear Linear
2 = 1 + stage 
of disease at 
diagnosis
Extent of disease 
(categorical)
Linear Linear 1.47 (1.26-1.68) 1.66 (1.18-2.13)
Tumor size (continuous) Linear Linear
3 = 2 + tumor 
characteristics
Histology (categorical) Linear Linear 1.45 (1.24-1.65) 1.65 (1.18-2.12)
4 = 3 + treatment Surgery (categorical) Linear Linear 1.44 (1.25-1.64) 1.66 (1.19-2.13)
Time to surgery 
(continuous)
Linear Not 
included
Final 
model
= 4 + 
Comorbidity
Charlson score 
(continuous)
Linear Linear 1.39 (1.20-1.59) 1.54 (1.10-1.98)
aThe number of women in the screen-detected group is the mean of the 10 imputed datasets and excludes women 
considered to be overdiagnosed.
Table 3: Sensitivity analysis of screening-specific excess hazard ratios at five years after diagnosis, comparing the 
most deprived to the least deprived group (reference)
Non-screen-detected Screen-detected
Baseline model Final model Baseline model Final model
Complete case n= 8,962 n= 8,541.5a
1.64 (1.41-1.87) 1.39 (1.20-1.59) 2.12 (1.48-2.76) 1.54 (1.10-1.98)
Sensitivity analysisb n= 9,624 n= 9012.9a
1.69 (1.46-1.92) 1.19 (1.03-1.35) 2.20 (1.55-2.84) 1.49 (1.06-1.91)
a The number of women in the screen-detected group is the mean of the 10 imputed datasets and excludes women 
considered to be overdiagnosed.
b Less deprived women with missing data assumed to have small, localized tumors whilst more deprived women with 
missing data are assumed to have large tumors with distant spread.
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in the excess hazard, even among screen-detected women, 
but that important deprivation differences still remain.
We were unable to adjust for other tumor factors 
including hormone receptor status as these variables were 
too incomplete. Surprisingly, surgical treatment received 
did not further explain differences in the excess hazard in 
either group, where previously this has been shown to be 
influential [8]. Additionally, time to surgery was not found 
here to improve the fit of any of the models for the screen-
detected group, similar to the findings of a recent smaller 
study [25]. However, the measure available was not very 
discriminatory, partly because almost all women had 
surgery, but also because information on hormone therapy, 
chemotherapy and radiotherapy were too incomplete to 
use. Administration of neo-adjuvant hormone therapy, not 
detectable in our data, might also have extended time to 
surgery for some women.
Comorbidities reduced the deprivation gap in the 
excess hazard by only a small amount, consistent with 
the fact that the cohort were ostensibly healthy younger 
women up to age 70. The impact of comorbidities upon 
socio-economic differences may be greater among older 
women [6, 8].
Our results suggest that factors other than stage 
of disease, tumor characteristics, surgical treatment and 
comorbidity lead to socio-economic differences in the 
excess hazard of breast cancer death, and that early, 
asymptomatic diagnosis via screening does not eliminate 
them. Differential use or receipt of treatments in breast 
cancer must be considered as an important potential 
explanation for this, and have previously been shown to 
be associated with socio-economic differences in survival 
[14, 15, 26–28]. It has been comprehensively shown 
that where treatment is consistent (within clinical teams 
or within clinical trials) socio-economic differences are 
not apparent [29, 30]. Differences in treatment actually 
received might originate from differences in ease of travel 
to appointments, flexibility of work, other commitments 
or levels of social support [31–33]. Differences in 
nutrition, smoking, alcohol consumption or other 
health-related behaviors are also possible explanations, 
although evidence for the impact of these upon cancer 
survival differentials is mixed [14]. The possibility of 
more frequent use of the screening service by more 
deprived women as a point of entry also deserves further 
examination.
Deprivation status is the socio-demographic 
characteristic that most strongly impacts the survival 
of women in the UK with breast cancer, after age at 
diagnosis. In this study, we have shown that the more 
deprived women with breast cancer have a higher excess 
hazard of cancer death, irrespective of whether their 
cancer was screen-detected or not. Our data suggest that 
this pattern is not simply a product of differences in timely 
diagnosis as it occurs even among women diagnosed 
asymptomatically. Having accounted here for some patient 
and tumor factors, we have shown that early diagnosis 
through screening is not enough to eliminate inequalities, 
and that the influence of differential cancer management, 
treatment, as well as lifestyles or life challenges of breast 
cancer patients from more deprived communities warrants 
further investigation.
MATERIALS AND METHODS
Data
As in our previous study,[5] the cohort consisted of 
women diagnosed with a primary, invasive breast cancer 
during the period 1 April 1989–31 March 2011, aged 50–
70 years at their diagnosis, who were continuously eligible 
for screening from the age of 50 up to either 65 or 70 
years (if the screening service expanded) and who would 
have received their first invitation letter from their 50th 
birthday onwards. A total of 20,283 women were included 
after excluding 761 women (3.6% of those eligible). These 
exclusions mainly comprised women whose tumors were 
recurrences of earlier malignancies. The mean date of 
diagnosis of these women was 14th August 2004. Cancer-
related information on these individuals was obtained from 
the West Midlands Breast Screening Quality Assurance 
Reference Centre (Cancer Registry) [34, 35]. These data 
were individually linked to Hospital Episode Statistics and 
the National Breast Screening Service records. The vital 
status of all women was known at the close of follow-up 
on 31 July 2012, after which each woman’s follow-up time 
was censored. The median follow-up time for all women 
was 5.77 years. For the 3,732 women who died during the 
study period median follow-up was 3.24 years.
Women whose breast cancer was not screen-detected 
included those whose last screening attendance had 
resulted in a negative screen and had not yet been invited 
to a subsequent screening (interval cancer; n=6,311, 
31.1%); women whose cancer was diagnosed after having 
previously had a negative screen, but who had not attended 
their most recent screening appointment (lapsed attenders, 
n=1,142, 5.6%); and women who had never presented for 
screening (non-attenders, n=2,310, 11.4%).
Deprivation was measured using the income domain 
of the English indices of multiple deprivation (IMD) for 
2004, 2007 or 2010 [36–38]. These ecologically-based 
scores are derived from routine administrative data 
pertaining to the years 2001, 2005 and 2008 respectively, 
and are calculated for each of the 32,482 Lower Super 
Output Areas as defined at the 2001 census (LSOAs, 
approximately 1,500 people). The scores are categorized 
according to the quintiles of their national distribution. 
Each woman was assigned to one of five deprivation 
levels on the basis of her address of residence and date of 
diagnosis. Those with missing information on deprivation 
were excluded from all analyses (18 women, 0.1%), 
resulting in 20,265 women in the analyses.
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Information on tumor size, nodal involvement 
and presence of metastases was used to establish each 
woman’s extent of disease at diagnosis, either localized 
(confined to the organ of origin), regional (spread to 
adjacent muscle, organ, fat, connective tissue or regional 
lymph nodes) or distant (distant metastases). Tumors were 
further categorized by their histology (ductal, lobular or all 
others) and grade (I, II or III).
Treatment was evaluated by surgery on the tumor 
within 6 months of diagnosis (yes/no), and time from 
diagnosis to first surgery. Information on radiology, 
chemotherapy and hormone therapy was too incomplete to 
be used (22.9%, 62.5% and 50.6% missing respectively).
Adjustment for lead time bias and over-diagnosis
Lead time bias arises from the inflation of an 
individual woman’s recorded survival due to the cancer 
being detected at an earlier point in time at screening, but 
with no associated improvement in prognosis. To account 
for this we applied the method established by Duffy et 
al [20]. Our approach has been described previously [5]. 
Briefly, for each patient, additional survival time due to 
screening, E(s), was estimated assuming an exponential 
distribution of survival times, and a mean sojourn time 
(from carcinogenesis to symptomatic detection) of 4 years. 
In order to account for the uncertainty associated with this 
value, we generated 10 separate data sets for the screen-
detected group containing E(s)1, E(s)2 … E(s)10 assuming 
these values were exponentially distributed with a mean 
of E(s).
Tumors are considered over-diagnosed if they would 
not have been detected symptomatically during the study 
period or during the woman’s predicted lifetime [39]. To 
account for overdiagnosis we excluded tumor records 
where the value of E(s) exceeded the woman’s actual 
observed survival time, was after 31st March 2011, or in 
excess of her life expectation at diagnosis (as defined in 
the life tables).
Modelling of excess hazard ratio
We fitted flexible parametric log-cumulative 
excess hazard regression models [40] to estimate the 
excess hazard ratio which compares the excess hazard 
of breast cancer death (the analog of net survival) in less 
deprived women to that in more deprived women during 
the first five years after diagnosis. The excess hazard is 
the hazard of death experienced by the cancer patients 
on top of their expected hazard of death. We used ethnic-
specific life tables for England and Wales adjusted for 
deprivation [41] to estimate expected mortality. Initial 
models were fitted separately for non-screen detected 
women, and for the 10 separate datasets derived for 
screen-detected women. These models included, a 
priori, age, year of diagnosis and deprivation category. 
We tested the linearity of age, year of diagnosis and 
deprivation category using Akaike’s Information 
Criterion (AIC). A reduction of 3 or more in the AIC 
between successive models was taken to show a better 
model fit [42]. We evaluated the time-varying effect 
of each variable by the inclusion of restricted cubic 
splines. We subsequently adjusted for the stage of the 
tumor (using the variables extent of disease and tumor 
size, including the time-varying effect of extent), tumor 
characteristics (using histological group), treatment 
(using surgery and time from diagnosis to first surgery) 
and the presence of comorbidity (using the Charlson 
score [43]). Size of tumor and time from diagnosis to 
first surgery were transformed prior to inclusion in the 
models. Grade of tumor was excluded since there was 
no evident association with deprivation (Table 1). We 
evaluated interactions between age and deprivation, 
extent of disease and deprivation, and period of diagnosis 
and deprivation.
This process resulted in one model final 
specification for the non-screen-detected group and 10 
different specifications for the screen-detected group. 
Eight out of these 10 were identical and thus defined the 
final specification (Appendix A).
We derived final estimates of the excess hazard 
ratio in the most deprived compared to the least deprived 
women using the final specifications. For the screen-
detected group, the final model specification was fitted 
to each of the 10 sets of data. We then applied the rules 
established by Rubin [44] for the re-combination of 
estimates in a multiple-imputation setting to derive an 
overall estimate of the hazard ratio and its variance in the 
screen-detected group, adjusted for lead time bias and 
over-diagnosis (Appendix B).
Sensitivity analyses for missing data
The initial models were derived using cases with 
complete records for all variables (93.1% among the non-
screen-detected, 94.8% among the screen detected). We 
conducted a sensitivity analysis to examine the possible 
impact of these missing data on our estimates. Where a 
variable of interest had more than 1% missing data (extent 
of disease, tumor size; Table 1) we imputed values which 
assumed that the less deprived women with missing data 
had tumors with much better prognosis. Specifically, 
values for extent of disease for the less deprived women 
(categories 1 and 2) were imputed as localized and tumor 
size to the mean size of localized tumors (16.6mm), whilst 
among the more deprived women (categories 3, 4 and 5) 
extent of disease was imputed as distant and tumor size to 
the mean size of distant tumors (47.8mm). Variables with 
less than 1% of missing data (histology and time to first 
surgery) were not considered and women with missing 
information for these variables were excluded from the 
analyses (0.6% and 0.4% respectively).
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